In a significant development for weight management therapies, a study presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans revealed that ecnoglutide, a new-generation GLP-1 receptor agonist, offers superior weight loss results compared to semaglutide. Conducted by Sciwind Biosciences, the SLIMMER-UP-SWITCH study demonstrated that ecnoglutide led to a 35% greater reduction in body weight and a 20% greater reduction in waist circumference by week 20 of the trial.

Study Details and Results

The study involved 163 adult patients with obesity across 17 research centers in China. Participants received weekly subcutaneous injections of either ecnoglutide or semaglutide. Results showed that 74% of patients in the ecnoglutide group achieved at least a 10% body weight reduction, compared to 40% in the semaglutide group. Additionally, ecnoglutide showed a significant advantage in reducing waist circumference, a key factor in managing risks associated with type 2 diabetes and cardiovascular diseases.

Innovative Mechanism and Safety

Ecnoglutide’s effectiveness is attributed to its cAMP-biased GLP-1 receptor agonist mechanism, which optimizes receptor signal transduction to enhance weight loss while maintaining a favorable safety profile. This approach addresses the common challenge of balancing efficacy with tolerability in weight loss therapies, as traditional GLP-1 receptor agonists often activate pathways associated with adverse gastrointestinal events.

Implications for Weight Management

The study’s findings mark an important milestone in the development of weight management therapies, offering new hope for patients struggling with obesity and related metabolic conditions. As the commercialization partner for ecnoglutide in China, Pfizer aims to expand access to this innovative therapy, providing patients with enhanced options for managing their weight effectively and safely.

Original reporting: KTBS 3 (Shreveport) — read the source article.